Continuing story · 1 report
Trump administration's ibogaine fast-track effort
DevelopingNext check : Whether the administration or FDA abandons the effort, or the FDA completes a decision on ibogaine’s development or approval pathway.
Where it stands
As of July 23, 2026, the Trump administration was pushing to fast-track ibogaine for addiction treatment, while experts cited cardiac risks linked to potentially fatal arrhythmias. The report identifies Trump and the FDA as decision-makers but gives no decision, next step or indication that the effort has been abandoned.
Story trackerDay 1
1 report11 outlets11 sources1 video
The story so far
Twenty-Seven Dead, No FDA Approval, and a Presidential Pen
Trump's April executive order fast-tracks ibogaine, a Schedule I psychedelic with documented cardiac risk, while Americans keep dying at unregulated clinics abroad.
Still open after this report
- The full death toll at foreign clinics, including non-American patients, is not publicly tracked.
- How the FDA will interpret "expedite" — whether it fast-tracks a specific application or reopens the research pathway — has not been disclosed.
- Whether Texas's state-funded trials will produce randomized data sufficient for an FDA submission.
History
Opened1 report
Who's involved
People
Céline GounderAmerican infectious disease physician, internist, epidemiologist, filmmaker, and medical journalist1 report
Donald TrumpPresident of the United States (2017–2021; since 2025)1 report
Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 report
Places
- MexicoMexico1 report
- Stanford University450 Jane Stanford Way, Stanford, CA 94305, USA1 report
- TexasTexas, USA1 report
- The Oval Office1600 Pennsylvania Ave NW, Washington, DC 20500, USA1 report
Every outlet we read on this story
11 sources11 outlets1 video
CBS Newscbsnews.com1
celinegounder.com1
HeyDay News11 video
modeldiplomat.com1
Newsweeknewsweek.com1
